ATE551357T1 - Markerpeptid für die alzheimer-krankheit - Google Patents

Markerpeptid für die alzheimer-krankheit

Info

Publication number
ATE551357T1
ATE551357T1 AT04799415T AT04799415T ATE551357T1 AT E551357 T1 ATE551357 T1 AT E551357T1 AT 04799415 T AT04799415 T AT 04799415T AT 04799415 T AT04799415 T AT 04799415T AT E551357 T1 ATE551357 T1 AT E551357T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
marker peptide
alcadein
peptide
Prior art date
Application number
AT04799415T
Other languages
English (en)
Inventor
Toshiharu Suzuki
Yoichi Araki
Naomi Miyagi-Toda
Haruyasu Yamaguchi
Masaki Nishimura
Kazuo Yamamoto
Original Assignee
Immuno Biological Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biological Lab Co Ltd filed Critical Immuno Biological Lab Co Ltd
Application granted granted Critical
Publication of ATE551357T1 publication Critical patent/ATE551357T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04799415T 2003-11-05 2004-11-01 Markerpeptid für die alzheimer-krankheit ATE551357T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003375363 2003-11-05
PCT/JP2004/016209 WO2005044847A1 (ja) 2003-11-05 2004-11-01 アルツハイマー病のマーカーペプチド

Publications (1)

Publication Number Publication Date
ATE551357T1 true ATE551357T1 (de) 2012-04-15

Family

ID=34567069

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04799415T ATE551357T1 (de) 2003-11-05 2004-11-01 Markerpeptid für die alzheimer-krankheit

Country Status (5)

Country Link
US (2) US7807777B2 (de)
EP (1) EP1690870B1 (de)
JP (1) JP5574559B2 (de)
AT (1) ATE551357T1 (de)
WO (1) WO2005044847A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US10850235B2 (en) 2006-10-09 2020-12-01 Minnetronix, Inc. Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow
EP2086573B1 (de) 2006-10-09 2020-11-25 Neurofluidics, Inc. System zur reinigung von liquor
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
DE102006048201A1 (de) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US20100323375A1 (en) * 2007-12-12 2010-12-23 Immuno-Biological Laboratories Co., Ltd. Agent and method for diagnosis on the occurrence of alzheimer's disease or the tendency to develop alzheimer's disease
TW201030337A (en) * 2009-02-04 2010-08-16 Tzu Chi Buddhist General Hospital Method and kit for detecting cancers
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
JP2014122788A (ja) * 2011-04-04 2014-07-03 Meneki Seibutsu Kenkyusho:Kk アルカデインペプチド切断物による認知症又はアルツハイマー病の診断方法又は予後予測方法
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
US10942190B2 (en) * 2014-01-21 2021-03-09 Shimadzu Corporation Measurement method for amyloid precursor protein cleavage peptides
US11147540B2 (en) 2015-07-01 2021-10-19 Minnetronix, Inc. Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue
CN108367102B (zh) 2015-08-05 2021-04-30 米奈特朗尼克斯有限公司 用于来自生物流体的物料的过滤的切向流过滤器系统
EP3842080B1 (de) 2015-12-04 2023-04-12 Minnetronix Inc. Systeme zur konditionierung von liquor
CN110426264B (zh) * 2019-08-27 2022-03-22 阜阳师范大学 一种脂肪细胞的染色方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422229A1 (en) 2000-09-14 2002-03-21 Universitat Zurich Calcium binding proteins
JP4056248B2 (ja) 2001-11-30 2008-03-05 武田薬品工業株式会社 アミロイドβタンパク質産生阻害薬のスクリーニング方法

Also Published As

Publication number Publication date
WO2005044847A1 (ja) 2005-05-19
JPWO2005044847A1 (ja) 2007-11-29
EP1690870A1 (de) 2006-08-16
EP1690870B1 (de) 2012-03-28
US7807777B2 (en) 2010-10-05
US20110014635A1 (en) 2011-01-20
JP5574559B2 (ja) 2014-08-20
US20070111252A1 (en) 2007-05-17
EP1690870A4 (de) 2007-08-08

Similar Documents

Publication Publication Date Title
ATE551357T1 (de) Markerpeptid für die alzheimer-krankheit
MY148086A (en) Antibodies directed against amyloid-beta peptide and methods using same
CY1110116T1 (el) Νευροεκφυλιστικοι δεικτες για καταθλιψη
WO2008021515A3 (en) Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
DE69929182D1 (de) Medizinische vorrichtung zur bergung von abgetrennten organteilen mittels schlingen
CY1110252T1 (el) Μεθοδος για την προβλεψη, διαγνωση και διαφορικη διαγνωση της νοσου του αλτζχαιμερ
AT500379B8 (de) Tau-proteine
EP1409544A4 (de) Humane dr4-antikörper und deren anwendungen
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
ATE520981T1 (de) Diagnose und überwachung von krankheiten
WO2005012530A3 (en) Antagonists and agonists of ldcam and methods of use
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
DE502004005226D1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
DE602004014127D1 (de) Silikon-modifiziertes Protein enthaltende Sonnenschutzzubereitung
DE60219645D1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
ATE500271T1 (de) Fluoresceinmarkierte peptide
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
ZA200603178B (en) Quick test for the diagnosis of Alzheimer's disease
EP1495056A4 (de) Antikörperdisulfidisomere, deren verwendung und verfahren zu deren analyse
BR0308978A (pt) fragmentos de peptìdeos sintéticos ativos
DE60334200D1 (de) Verfahren zur messung von neprilysinaktivität
DE60105609T8 (de) Metabolismuskontrolle mittels zusammensetzungen des humanen 2-oxoglutarat-trägers
WO2006093973A3 (en) Biomarkers of vulnerable a therosclerotic plaques and methods of use
ATE511643T1 (de) Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer